Home »
Rulemaking » Agency Information Collection Activities; Proposals, Submissions, and Approvals: Communicating Composite Scores in Direct-to-Consumer Advertising
Agency Information Collection Activities; Proposals, Submissions, and Approvals: Communicating Composite Scores in Direct-to-Consumer Advertising
October 22 2012, at 11:59 PM Eastern Standard Time
Attachments:
Reference 1 From Idea to Market The Drug Approval Process
View Attachment:
Title: Reference 1 From Idea to Market The Drug Approval Process
Reference 2 Guidance of Industry Postmarketing Studies and Clinical Trials Implementatioon of Section 505 (o)(3) of the Federal Food Drug and Cosmetic Act
View Attachment:
Title: Reference 2 Guidance of Industry Postmarketing Studies and Clinical Trials Implementatioon of Section 505 (o)(3) of the Federal Food Drug and Cosmetic Act
Reference 3 A Historical Perspective of Elevated Systolic vs Diastolic Blood Pressure From an Epidemiological and Clinical Trial Viewpoint
View Attachment:
Title: Reference 3 A Historical Perspective of Elevated Systolic vs Diastolic Blood Pressure From an Epidemiological and Clinical Trial Viewpoint
Reference 4 Combining Measures Into Composite or Summary Scores
View Attachment:
Title: Reference 4 Combining Measures Into Composite or Summary Scores
Reference 5 Measures Development, Methodology, and Oversight Advisory Committee: Recommendations to PCPI Work Groups on Composite Measures
View Attachment:
Title: Reference 5 Measures Development, Methodology, and Oversight Advisory Committee: Recommendations to PCPI Work Groups on Composite Measures
Reference 6 Quantitative Information
View Attachment:
Title: Reference 6 Quantitative Information
Reference 7 Numeracy and Decision Making
View Attachment:
Title: Reference 7 Numeracy and Decision Making
Reference 8 The Effects of Numerical Statements of Risk on Trust and Comfort With Hypothetical Physician Risk Communication
View Attachment:
Title: Reference 8 The Effects of Numerical Statements of Risk on Trust and Comfort With Hypothetical Physician Risk Communication
Reference 9 Presenting Risk Information to People With Diabetes: Evaluating Effects and Preferences for Different Formats by a Web-Based Randomized Controlled Trial
View Attachment:
Title: Reference 9 Presenting Risk Information to People With Diabetes: Evaluating Effects and Preferences for Different Formats by a Web-Based Randomized Controlled Trial
Agency Information Collection Activities; Proposals, Submissions, and Approvals: Communicating Composite Scores in Direct-to-Consumer Advertising
Details Information
Attachments:
Reference 1 From Idea to Market The Drug Approval Process
View Attachment:Reference 2 Guidance of Industry Postmarketing Studies and Clinical Trials Implementatioon of Section 505 (o)(3) of the Federal Food Drug and Cosmetic Act
View Attachment:Reference 3 A Historical Perspective of Elevated Systolic vs Diastolic Blood Pressure From an Epidemiological and Clinical Trial Viewpoint
View Attachment:Reference 4 Combining Measures Into Composite or Summary Scores
View Attachment:Reference 5 Measures Development, Methodology, and Oversight Advisory Committee: Recommendations to PCPI Work Groups on Composite Measures
View Attachment:Reference 6 Quantitative Information
View Attachment:Reference 7 Numeracy and Decision Making
View Attachment:Reference 8 The Effects of Numerical Statements of Risk on Trust and Comfort With Hypothetical Physician Risk Communication
View Attachment:Reference 9 Presenting Risk Information to People With Diabetes: Evaluating Effects and Preferences for Different Formats by a Web-Based Randomized Controlled Trial
View Attachment:Comments
Posted: 11/02/2012 ID: FDA-2012-N-0892-0002
Oct 22,2012 11:59 PM ET
Related Documents